![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 39, 36295-36302, September 28, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,From the Department of Cell and Tumor Biology, City of Hope National Medical Center, Duarte, California 91010
Received for publication, April 17, 2001, and in revised form, July 9, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Interaction between human flap endonuclease-1
(hFEN-1) and proliferating cell nuclear antigen (PCNA) represents a
good model for interactions between multiple functional proteins
involved in DNA metabolic pathways. A region of 9 conserved amino acid residues (residues Gln-337 through Lys-345) in the C terminus of human
FEN-1 (hFEN-1) was shown to be responsible for the interaction with
PCNA. Our current study indicates that 4 amino acid residues in hFEN-1
(Leu-340, Asp-341, Phe-343, and Phe-344) are critical for human PCNA
(hPCNA) interaction. A conserved PCNA interaction motif in various
proteins from assorted species has been defined as
Q1X2X3(L/I)4X5X6F7(F/Y)8,
although our results fail to implicate Q1 (Gln-337 in
hFEN-1) as a crucial residue. Surprisingly, all hFEN-1 mutants,
including L340A, D341A, F343A, and F344A, retained hPCNA-mediated
stimulation of both exo- and flap endonuclease activities. Furthermore,
our in vitro assay showed that hPCNA failed to bind to the
scRad27 (yeast homolog of FEN-1) nuclease. However, its nuclease
activities were significantly enhanced in the presence of hPCNA. Four
additional Saccharomyces cerevisiae scRad27 mutants,
including multiple alanine mutants and a deletion mutant of the entire
PCNA binding region, were constructed to confirm this result. All of
these mutants retained PCNA-driven nuclease activity stimulation. We
therefore conclude that stimulation of eukaryotic hFEN-1
nuclease activities by PCNA is independent of its in vitro
interaction via the PCNA binding region.
DNA replication and repair are critical for maintaining
genome stability. These processes are in part dependent on the
activities of an emerging family of structure-specific endonucleases.
These enzymes, typified by eukaryotic flap endonuclease-1
(FEN-1),1 are substrate
structure-specific and multifunctional (1-3). They possess both
flap-specific endonuclease and nick-specific exonuclease (ribonuclease)
activities and interact with proliferating cell nuclear antigen (PCNA)
as well as other proteins (3-5). This unique substrate-specific nature
is based on structural elements that have been observed in the
three-dimensional structures of prokaryotic FEN-1 homologues (6-10).
The N-terminal region and the region located in between the two
conserved nuclease motifs three-dimensionally form an arch, thus
creating a hole in the middle of the protein. The dimensions of the
hole only allow single-stranded DNA, but not double-stranded DNA, to
thread through. The presence of positively charged and bulky residues
in the helices of the arch region may directly interact with DNA
substrate. Other structural features, such as the H3TH motif,
dynamically hold the double-stranded portion of the flap substrate (7).
Therefore, hFEN-1 nuclease is able to recognize the ends of free 5'
single strand DNA and thread it through the hole, resulting in cleavage
at the junction between the single-stranded and double-stranded DNA
portions of the substrate (11). At the cellular level, hFEN-1 nuclease
is able to localize into nuclei in a cell cycle-dependent
and DNA damage-inducible manner (12). To date, nine different proteins involved in DNA metabolic pathways have been reported to interact with
hFEN-1 nuclease. They include PCNA, APE-1, Dna2 helicase, RPA,
replication factor C (RF-C), pol
Among these FEN-1 interactive proteins, PCNA has been studied
intensively. It was originally identified as a processivity factor for
DNA polymerase The Lieber and Burgers group was the first to report that human and
yeast PCNA (hPCNA and scPCNA) interacts with the hFEN-1 and scRad27
nucleases and stimulates their activities, respectively (5, 15). Using
the yeast two-hybrid system, Li et al. (15) demonstrated
that yeast scRad27 directly binds to scPCNA. This specific interaction
was further confirmed by affinity chromatography using scPCNA beads and
yeast cell crude extract containing scRad27. Through protein-protein
interactions, PCNA focuses hFEN-1 on a branched DNA substrate (flap
endonuclease substrate) and on a nicked DNA substrate (exonuclease
substrate), thereby stimulating its activity 10-50-fold depending on
the salt concentrations used in the reactions (5). The exact mechanism
of stimulation remains unclear. Recent in vitro studies
suggest that PCNA stimulates nuclease activities by lowering the
Km value of hFEN-1 for DNA substrates (31).
Additionally, there are two regions in PCNA that have been shown to be
potential binding sites for hFEN-1. The first of these regions is
located in the interdomain connector loop (IDCL) of PCNA (32), and the
second sequence is found near the C terminus of PCNA (21, 33). FEN-1 is
critical during Okazaki fragment maturation on the lagging strand.
FEN-1 helps remove RNA primers in a process during which it either
functions alone as an endonuclease or as an exonuclease in cooperation
with RNase H (34, 35). In vitro stimulation of hFEN-1
endonuclease and exonuclease activities by PCNA suggests that this
phenomenon may be important during DNA replication in vivo.
In addition, the interaction of FEN-1 and PCNA has also been shown to
be important for DNA repair, specifically for the removal of oxidative
base damage via long patch base excision repair (36-38). The absence of PCNA in reconstituted in vitro base excision repair
reactions containing FEN-1 results in an accumulation of uncleaved or
unprocessed damaged DNA intermediates (36). A defective hFEN-1·hPCNA
complex may result in inefficient removal of certain types of DNA
damage or improper processing of Okazaki fragments, which can produce DNA with secondary structure and eventually result in duplication mutations. The accumulation of DNA damage and increased rates of
duplication mutations are examples of primary molecular events that may
lead to human cancers and heritable genetic diseases such as colorectal
cancers, Huntington's disease, and various ataxias (2, 39, 40).
Via peptide mapping experiments and protein truncation analysis, a
conserved region in the C terminus of the hFEN-1 nuclease (337QGRLDDFFK345) has been shown to be the PCNA
interaction region (23, 32). When this region is deleted, or, when two
critical amino acid residues (Phe-343 and Phe-344) were mutated to
alanines, the in vitro binding ability of hFEN-1 to hPCNA
was eliminated (36). In this study, we aimed to elucidate details of
the structural and functional relationship of this interaction.
Comprehensive alanine mutagenesis was performed in the entire proposed
PCNA interaction region. Our results demonstrate that 4 amino acid residues in hFEN-1, Leu-340, Asp-341, Phe-343, and Phe-344, were critical for the in vitro interaction with hPCNA. Individual
replacement of each of these 4 amino acid residues with alanine
resulted in a loss of interaction with hPCNA in vitro.
Unexpectedly, all hFEN-1 mutants, including L340A, D341A, F343A, and
F344A, retained hPCNA-mediated stimulation properties of both
exonuclease and flap endonuclease activities. Further functional
interaction analyses of scRad27 nuclease mutants were also carried out.
These mutants include multiple alanine mutations of L340/F343/F344,
L340/D341/F343/F344, or 337QGRLDDFF344 or a
deletion of these 8 amino acid residues (337) in the PCNA-binding region. These alterations resulted in the loss of PCNA binding but
retained nuclease activity stimulation. Additionally, human PCNA fails
to interact with the scRad27 nuclease, yet it is still able to
stimulate the nuclease activities of scRad27. These results suggest
that the in vitro interaction of hFEN-1/scRad27 to PCNA and
stimulation of nuclease activities are mediated through independent mechanisms.
Site-directed Mutagenesis of FEN-1 and RAD27--
All mutant
proteins created for this study were prepared using the QuikChangeTM
site-directed mutagenesis kit from Stratagene (La Jolla, CA). A pair of
mutagenic primers for each mutant was synthesized at the City of Hope
DNA/RNA/peptide synthesis core facility. All together, 12 mutants of
human FEN-1 and yeast Rad27 were made for this study. Mutations and
corresponding oligo sequences are listed in Table I for clarity.
Mutagenesis reactions contain 50 ng of template pET28 derived plasmids
harboring the wild type FEN-1 (41), RAD27 (34),
or the 3A rad27 mutant (this study) gene sequence, 125 ng of
each primer, a 10 mM dNTP mix, and 1 µl (2.5 units/µl)
of Pfu polymerase, and then subjected to thermal cycling.
Polymerase chain reactions were carried out with the following
parameters: 95 °C for 30 s (one cycle only), followed by 16 cycles of 95 °C for 30 s, 55 °C for 1 min, and 68 °C for 14 min according to the manufacturer's instructions (Stratagene, La
Jolla, CA). After thermal cycling, 10 units of DpnI
restriction enzyme was added to each reaction to digest parental
template DNA. DpnI-digested samples were then transformed
into Escherichia coli DH5 Protein Overexpression and Purification--
Protocols for
protein overexpression and purification have been described in our
previous work (34, 42). After transformed E. coli BL21(DE3)
cells were amplified, protein expression was induced by
isopropyl- FEN-1·PCNA Binding Assays--
A binding assay protocol was
designed based on the published methods developed by Gary et
al. (36) and Stucki et al. (43). Briefly, cells
harboring the wild type or mutant His-tagged human FEN-1 or yeast Rad27
protein, and non-histidine-tagged human or yeast PCNAs were grown,
induced, and harvested as described previously (34, 42). Binding
reactions contain 150 µl of crude cell extracts of the appropriate
FEN-1 or Rad27 protein and the appropriate PCNA protein, 150 µl of a
50% slurry of beads charged with 50 mM NiSO4
and 450 µl of Tris-based buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl). To facilitate the protein-protein
interaction, samples were gently shaken at 4 °C for 90 min. Beads
were collected by gravity and then washed four times with wash buffer
(50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 60 mM imidazole). Following the final wash, beads were
resuspended in 75 µl of 2× protein sample loading buffer (100 mM Tris, pH 6.8, 200 mM dithiothreitol, 4%
SDS, 0.2% bromphenol blue, 20% glycerol), boiled, the supernatant was
collected, followed by analysis using SDS-PAGE. The gel was stained
with Coomassie Blue R250 for visualization of proteins that were bound
to the beads. A FEN-1·PCNA complex was confirmed by visualizing the
presence of both a protein band for hFEN-1 (~42 kDa) or scRad27
(~42 kDa) and a band for human or yeast PCNA (~31 and 29 kDa,
respectively) on the gel.
DNA Substrate Preparation and PCNA-dependent FEN-1
Nuclease Activity Assays--
The following four oligos were
synthesized at the City Of Hope DNA/RNA/peptide synthesis
facility and were used to prepare the flap endonuclease and exonuclease
substrates: Flap-G1 (5'-GATGTCAAGCAGTCCTAACTTTGAGGCAGAGTCC-3'), Temp-1G (5'-GGACTCTGCCTCAAGACGGTAGTCAACGTG-3'), Prim-3B
(5'-CACGTTGACTACCGTC-3'), and Exo-3PT (5'-TTGAGGCAGAGTCC-3'). Flap-G1
(labeled oligo of the flap substrate) and Exo-3PT (labeled oligo of the
exonuclease substrate) were 5' end-phosphorylated by incubating 40 pmol
of oligo with 10 µCi of [
For PCNA-independent assays, reactions were carried out with 120 fmol
of hFEN-1 or scRad27 and 500 fmol of flap or exonuclease substrate in
13 µl of 50 mM Tris (pH 8.0), 10 mM
MgCl2, and 100 µg/ml BSA. For PCNA-dependent
flap endonuclease activity stimulation assays, 120 fmol of the
appropriate FEN-1 or Rad27 was mixed with 2.6 µl of 5× reaction
buffer with high salt concentration (250 mM Tris-Cl, pH
8.0, 50 mM MgCl2, 375 mM NaCl), 500 fmol of flap substrate, and 3,000 fmol of human or yeast PCNA. Each
reaction was then brought to a total volume of 13 µl with water. As
for the PCNA-dependent exonuclease activity stimulation
assays, 240 fmol of FEN-1 or Rad27 protein, 3,000 fmol of human or
yeast PCNA, and 500 fmol of exonuclease substrate were mixed with 2.6 µl of 5× reaction buffer with low salt concentration (250 mM Tris-Cl, pH 8.0, 50 mM MgCl2,
and 125 mM NaCl). Each reaction was then brought to a total
volume of 13 µl with water. All reactions were incubated at 30 °C
for 15 min and terminated by adding an equal volume of stop solution
(95% formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.05%
xylene cyanol). An aliquot of each reaction was then run on a 15%
denaturing PAGE at 1900 V for 1 h. The gel was dried at 70 °C
for 50 min, and then visualized by autoradiography.
Identification of hFEN-1 Residues That Are Crucial for hPCNA
Binding--
Previous studies have determined some of the amino acid
residues in the C-terminal region of hFEN-1 that are crucial for its ability to bind hPCNA (23, 32). Our current study aimed to comprehensively analyze each amino acid residue in the consensus PCNA
binding region of hFEN-1 to determine which residues were necessary for
binding. Based on previous findings, we chose to focus on the region of
hFEN-1 that includes residues Gln-337 through Lys-345 (3, 12, 32). This
region resembles the consensus conserved PCNA binding motif,
Q1X2X3(L/I)4X5X6F7(F/Y)8. The residues in bold are conserved in many FEN-1 nuclease homologs and
some other PCNA interacting proteins, as shown in Table II, and serve
as excellent candidates to begin mutagenic analysis.
We individually mutated 8 of the 9 amino acids in this region to
alanine in order to study the PCNA binding role of each residue. The
ninth residue, glycine, was excluded in the individual mutational analysis, but was later included in a mutant containing multiple mutations (termed the 8A mutant, see below). Our study indicates that
residues Leu-340, Asp-341, Phe-343, and Phe-344 are crucial for
the hFEN-1-hPCNA interaction (Fig.
1). Surprisingly, Gln-337 was not
important even though this glutamine residue is highly conserved in the
PCNA interacting proteins listed in Table II. This result may indicate
that the putative PCNA binding motif in the FEN-1/XPG family is
actually shorter than proposed and only resembles a motif such as
(L/I)1(D/E)2X3(F/W)4F5.
Nuclease Activity Stimulation of Mutant hFEN-1 Proteins by
hPCNA--
It has been shown previously that hFEN-1 endonuclease and
exonuclease cleavage activities can be stimulated 10-50-fold by the
presence of hPCNA provided that the NaCl concentration is similar to
that of physiological conditions (15). This phenomenon occurs because
the presence of NaCl inhibits hFEN-1 activity in vitro, and
it is the presence of hPCNA that allows hFEN-1 to overcome this
inhibition. Each of the eight mutant hFEN-1 proteins created in this
study was highly purified in order to analyze in vitro stimulation of endonuclease and exonuclease activities by hPCNA. Logically, one would expect that all mutants that retained binding ability would still be stimulated by hPCNA. Likewise, all mutants that
lost their binding ability would also lose their ability to be
stimulated. To perform PCNA-dependent nuclease activity assays, we chose to use linearized DNA oligo substrates as shown in
Fig. 2 (A and B),
which are identical to the substrates used in the original report by
Lieber and Burgers (15). Endonuclease and exonuclease activities
of each mutant were first tested in the absence of NaCl to confirm that
each protein was functional as described under "Materials and
Methods" (data not shown). Following this confirmation, we
individually assayed the stimulation of both endonuclease and
exonuclease cleavage for the eight mutant hFEN-1 proteins as well as
the wild type protein. Interestingly, we observed that endonuclease
activity of all eight mutants was still stimulated by hPCNA (Fig.
2A). In agreement with these results, we also observed that
exonuclease activity of all eight mutants was also stimulated by hPCNA
(Fig. 2B). These results were quite unexpected. One
observation of importance is that previously created PCNA
binding-deficient hFEN-1 and scRad27 mutants have never been assayed
for stimulation (e.g. Refs. 36 and 44). Our analysis of the
hPCNA-mediated stimulation of hFEN-1 mutant nuclease activity clearly
demonstrates that amino acid residues, which were shown to be necessary
for binding, were not required for stimulation.
hFEN-1 or Rad27 Binding and Activity Stimulation by Human and Yeast
PCNA--
When the Lieber and Burgers' group first demonstrated the
intraspecies interaction and stimulation between hFEN-1/scRad27 and its
respective PCNA, they also reported that the interspecies stimulation
of hFEN-1 by scPCNA was poor (5). This observation was then utilized to
explain genetic data obtained in rad27 mutant complementation experiments by hFEN-1(44, 45). Our current work was
designed to determine if the human and S. cerevisiae PCNA proteins (hPCNA and scPCNA, respectively) were able to bind to hFEN-1
or scRad27 and stimulate the nuclease activities intra- and
interspecifically. First, we tested the ability of both PCNAs to bind
to hFEN-1 or scRad27. Fig. 3 shows the
interspecific binding properties of hFEN-1 and scRad27 to human and
yeast PCNA. The data indicate that hFEN-1 binds to hPCNA and scPCNA
with no apparent qualitative difference. scRad27 binds only to scPCNA
under the same reaction conditions, whereas it failed to bind to hPCNA. This indicates that the regions of hPCNA and scPCNA where hFEN-1 binds
are similar enough that hFEN-1 is unable to discriminate between the
two sites. On the other hand, the results in Fig. 3 also show that
scRad27 is able to bind scPCNA, but not hPCNA. This may illustrate
subtle differences of hFEN-1 and scRad27 binding to PCNA from
different species.
Additionally, using hPCNA and scPCNA, we assayed the stimulation of
flap endonuclease and exonuclease activities of hFEN-1 and scRad27, and
we clearly demonstrated that nuclease activities are stimulated in the
presence of hPCNA or scPCNA (Fig. 4).
Even though the interspecific binding abilities of hFEN-1 and scRad27 differ, it is clear that both proteins are stimulated by the
corresponding interspecific PCNA to a similar degree. Again, these data
further confirm the fact that deficiency of our hFEN-1 mutants in hPCNA binding does not necessarily correlate with stimulation of nuclease activities.
Multiple Mutations of Conserved Residues in the PCNA Interaction
Motif of Rad27--
Our study has identified the residues critical for
hFEN-1 binding to hPCNA, whereas additional data have detailed which
residues are important for PCNA binding by other proteins such as
ligase I, p21, and MCMT (Table II) (23, 24, 44, 46). Our experiments have also demonstrated that the nuclease activities of single amino
acid mutants can still be stimulated by hPCNA. One of the possible
explanations is that the presence of other unidentified conserved
residues in the PCNA binding region are able to serve as a back-up for
stimulation by compensating for single residue mutations. Three
residues (LXXFF) in this motif are highly conserved and are
essential for binding to PCNA by ligase I, p21, MCMT, hFEN-1, and
scRad27 (23, 24, 32, 44, 46, 47). These residues are equivalent to the
Leu-340, Phe-343, and Phe-344 residues in hFEN-1 and the Leu-343,
Phe-346, and Phe-347 residues in scRad27. We mutagenized these residues
in scRad27 to alanine (L343A/F346A/F347A, termed the 3A mutant
hereafter). We opted to create this mutant in scRad27 so that it could
potentially be used for future in vivo studies in S. cerevisiae. Characterization of the 3A mutant was performed as
with the single mutant hFEN-1 proteins. Binding assays of the 3A mutant
revealed that this mutant lost its ability to bind to scPCNA (Fig.
5). scPCNA-dependent
endonuclease and exonuclease activity assays were also performed.
Clearly, the endonuclease and exonuclease activities of the 3A mutant
were significantly enhanced by scPCNA (Fig.
6). However, there is an additional
conserved amino acid residue, Gln-337 in hFEN-1, which is highly
conserved in PCNA-binding proteins, but has been experimentally proven
to not be critical for hFEN-1 binding to hPCNA. In order to clearly
demonstrate that the glutamine residue plays no role in binding or
stimulation, we constructed a quadruple mutant in scRad27
(Q340A/L343A/F346A/F347A, termed the 4A mutant hereafter). The binding
(Fig. 5) and stimulation assays (Fig. 6) of the 4A mutant resulted in
data similar to that for the 3A mutant and to the single mutants of
hFEN-1. These data indicate that multiple mutations of conserved
residues in the putative PCNA binding region do not abolish in
vitro PCNA-mediated stimulation of nuclease activities. These
properties led us to believe that more comprehensive group mutations,
or a deletion of the entire region, may be necessary to create a mutant
that cannot have its nuclease activities stimulated.
Recently, Stucki et al. (43) constructed a deletion mutant
of hFEN-1 (FEN-1
As expected, both the 8A and Employing a strategy of individually mutating each of the 8 amino
acid residues to alanine residues in the C-terminal putative hPCNA
binding motif of hFEN-1 (Table II) allowed us to systematically analyze
hFEN-1's ability to bind to hPCNA as well as to determine the effect
on the stimulation of its nuclease activities by hPCNA. Our intentions
were to precisely determine which residues in hFEN-1 are crucial for
binding to hPCNA and then correlate the binding results of individual
mutants with their stimulation properties. Our results revealed
interesting and novel findings that should expand our overall knowledge
of hFEN-1's in vitro binding and stimulation
characteristics and may help to further our understanding of previously
published in vivo results.
Previous biochemical analysis of PCNA and its interaction with various
proteins revealed a conserved sequence in these proteins that is
necessary for their ability to bind to PCNA. An 8-amino acid residue
consensus PCNA binding motif was derived and is represented by the
following sequence:
Q1X2X3(L/I)4X5X6F7(F/Y)8. Traditionally, this motif is located at, or near, either the N or C
terminus of PCNA-binding proteins. In Table II, boldface letters in the
putative PCNA binding motifs of various proteins indicate that residues
are highly conserved. Mutational analysis of this motif in hFEN-1 was
performed in order to determine the identity of the residues essential
for binding to PCNA. Previous analysis of five proteins has partially
determined the residues that were essential for PCNA binding by the
scRad27, hFEN-1, p21, ligase I, and MCMT proteins (23-25, 32, 44, 46,
47). Residues equivalent to (L/I)4, F7, and
(F/Y)8 of the PCNA consensus binding motif are essential
for PCNA binding by all five proteins. In our current study, point
mutations in the consensus PCNA binding motif of
hFEN-1 were created and characterized. Binding
analysis of each mutant using crude cell extracts unambiguously showed which residues were essential for hFEN-1 to bind to hPCNA (Fig. 1). In
the C-terminal PCNA binding region of hFEN-1, we determined that
residues Leu-340, Asp-341, Phe-343, and Phe-344 (equivalent to Leu-343,
Asp-344, Phe-346, and Phe-347 in scRad27) were essential for binding.
Our experiments further confirmed that the glutamine residue is not
essential for the hFEN-1-hPCNA interaction and may not actually be a
part of the PCNA binding motif even though it is highly conserved.
Instead, aspartate 341, which is conserved in the eukaryotic FEN-1/XPG
nuclease family, is a crucial residue in the consensus motif (Table
II). Our results suggest that the consensus PCNA binding motif for the
FEN-1/XPG family could be better represented as
(L/I)1(D/E)2X3(F/W)4F5.
The most interesting and unexpected results obtained in this study
involved the analysis of the hPCNA-mediated stimulation of the nuclease
activities of hFEN-1 and scRad27 proteins that contained single or
multiple mutations in the C-terminal PCNA interaction domain. In order
to correlate the experimentally observed binding abilities of mutants
with their stimulation properties, all mutant hFEN-1s were analyzed for
their hPCNA-mediated flap endonuclease and exonuclease stimulation
using in vitro assays (5, 43). We predicted that all mutants
that lost binding ability to hPCNA would also lose their ability to be
stimulated, and, likewise, mutants that retained binding ability would
also retain hPCNA-mediated stimulation of their endo/exonuclease
activities. However, all mutants created still retained hPCNA-mediated
stimulation of flap endonuclease (Fig. 2A) and exonuclease
(Fig. 2B) activities. It was also considered that the
presence of PCNA could produce an excluded volume effect similar to the
mechanism in which the presence of excess BSA is able to enhance the
activity of some restriction enzymes. This possibility was tested using
BSA and polyethylene glycol 4000 and observed that this was not the
case (data not shown). Alternatively, we also considered the
possibility that an undetectable amount of residual binding to hPCNA
may exist in any (or all) of the hPCNA binding deficient single mutants because our binding assay may not be sensitive enough to detect residual binding levels. Therefore, we addressed this possibility by
mutating multiple conserved residues in combination. The following four
mutants of scRad27 were also constructed for this experiment: 1) a
triple mutant by changing Leu-343, Phe-346, and Phe-347 all to alanines
(3A mutant), 2) a quadruple mutant by changing Gln-340, Leu-343,
Phe-346, and Phe-347 all to alanines (4A mutant), 3) a mutant in which
residues Gln-340 through Phe-347 were all changed to alanines (8A
mutant), and 4) a mutant with a deletion of these 8 residues ( This finding was supported by our further observation that hPCNA was
able to stimulate nuclease activities of scRad27 even though it can not
bind to scRad27. The original purpose for performing the experiment on
interspecific binding and stimulation of hFEN-1 and scRad27 proteins by
human or yeast PCNAs was to verify the previous data that scPCNA could
not stimulate hFEN-1 nuclease activities (5). Our recent observation
shows that hFEN-1 could fully complement scRad27 functions when it was
used to rescue rad27 knockout strains (26). This result led
us to hypothesize that the scPCNA should be able to bind to hFEN-1 and
stimulate its nuclease activities or vice versa. As expected, our
present study indicated that the scPCNA could indeed bind to hFEN-1
protein (Fig. 3) and stimulate its nuclease activities (Fig. 4)
in vitro. Unexpectedly, we also revealed that hPCNA could
stimulates the nuclease activities of scRad27, but was not able to bind
to the protein, which support our hypothesis that the binding and
stimulation of FEN-1 proteins by PCNA are mediated via independent mechanisms.
The above results led us to consider the possible existence of
additional unidentified motif(s) and/or structural elements in RAD27
(or hFEN-1) that could be responsible for the stimulation properties of
the wild type and various mutant proteins by PCNA. In a recent report,
Gomes and Burgers (48) described that the ability of scRad27 to bind to
two distinct regions in scPCNA (the IDCL and C terminus) was regulated
by DNA. A yeast IDCL mutant, pcna-79 (IL126, 128AA), failed to interact
with scRad27 in solution, but surprisingly, was still very active in
stimulating scRad27 nuclease activity. In contrast, a C-terminal
mutant, pcna-90 (PK252, 253AA), exhibited wild type binding to scRad27
in solution, yet poorly stimulated the nuclease activities of scRad27.
When proteins were individually loaded onto a DNA substrate (resembling
our exonuclease substrate) that was coupled to magnetic beads, wild type scPCNA and pcna-79, but not pcna-90, formed a complex with scRad27
and the DNA substrate. These results indicated that the presence of an
appropriate DNA substrate dictated the region of PCNA to which Rad27 binds.
The data presented here are contradictory to what Stucki et
al. (43) have published recently. Stucki et al.
constructed a deletion mutant of hFEN-1 lacking the PCNA interaction
motif, which is equivalent to our
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
, pol
, pol
, and type II DNA topisomerase (13-18). All of
these proteins are essentially involved in two different general
cellular processes, namely DNA replication and DNA base damage repair,
which is consistent with the dual roles of hFEN-1 in DNA replication
and repair.
(19, 20) and
(21). PCNA functions as a
homotrimer with a subunit molecular mass of 31 kDa for hPCNA (29 kDa
for scPCNA) and is highly conserved from yeast to mammalian cells (22).
Besides its roles in DNA replication, PCNA has been shown to be a
critical regulating factor through its interaction with various
important proteins involved in repair and cell cycle control including
xeroderma pigmentosum group G (XPG) nuclease (23), DNA (cytosine-5)
methyltransferase (MCMT) (24), p21 (25), MSH2 (26), and MSH3 (27).
In vitro experiments have revealed that PCNA can bind to
these proteins and can also stimulate specific enzymatic activities.
Under native conditions PCNA exists as a monomer and must homotrimerize
in order for it to encircle DNA. PCNA can trimerize around
double-stranded DNA by simple diffusion or trimerize first and slide
onto DNA provided there are free ends. However, it is most efficiently
loaded as a trimer onto closed circular double-stranded DNA by the
accessory protein RF-C in an ATP-dependent process (28,
29). The crystal structure of scPCNA shows that the trimer forms a
closed ring with appropriate dimensions and electrostatic properties
that enable it to encircle double-stranded DNA and to interact with DNA
using nonspecific contacts (30). Processivity during DNA synthesis is
achieved by a direct protein-protein interaction between PCNA and
polymerase
as PCNA tethers the DNA polymerase at the primer
terminus. Once loaded onto DNA, RF-C dissociates from the DNA template
while PCNA remains encircled around the template in order to tether DNA
polymerase
to DNA, thus enabling it to participate in both leading
and lagging strand DNA synthesis. After PCNA is loaded onto DNA, it is
able to freely slide on the DNA template in either direction (29).
hFEN-1 and Rad27 mutants constructed in this study and oligos used for
mutagenesis
Conserved PCNA binding motif of FEN-1 nucleases and other DNA metabolic
proteins
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-competent cells. Individual
colonies were picked. Plasmid DNA was purified using a minipreparation
kit (Qiagen, Valencia, CA). DNA sequence analysis was performed at the
City of Hope DNA sequencing facility to verify the alterations. After
confirming the mutation, the desired plasmid DNA was then transformed
into E. coli BL21(DE3) cells for protein overexpression.
-D-thiogalactopyranoside, cells were
harvested, soluble FEN-1 and Rad27 wild type and mutant proteins were
extracted in a Tris-based buffer (20 mM Tris, pH 7.9, 150 mM NaCl) and were bound to a 5-ml Ni2+
chelating column, which is facilitated by a fast protein liquid chromatography system (Amersham Pharmacia Biotech). The column was then
washed with 40 mM imidazole, and specifically bound protein was eluted over a gradient spanning a concentration range from 40 to
350 mM imidazole over a total volume of 50 ml. Fractions were collected in 2-ml aliquots for a total of 25 fractions, and appropriate fractions were analyzed using SDS-PAGE to determine which
ones contained purified protein. Fractions containing the desired
protein were pooled and then exchanged into a buffer of 20 mM Tris-Cl, pH 7.9, 150 mM NaCl using a
de-salting column (Amersham Pharmacia Biotech). Protein concentration
was determined using the Bio-Rad (Bradford) protein assay reagents, and
then an equal volume of glycerol was added to each protein sample for
storage at
20 °C.
-32P]ATP and 1 µl (10 units/µl) of polynucleotide kinase at 37 °C for 60 min.
Polynucleotide kinase enzyme was inactivated by heating the sample at
72 °C for 10 min. 80 pmol each of the Temp-3B and Prim-1G oligos
were then added to the labeled oligos, respectively. The samples were
incubated at 70 °C for 5 min, followed by slow cooling to 25 °C
to allow the oligos to slowly anneal and form the flap endonuclease and
exonuclease substrates as shown in Fig. 2 (A and
B). Substrates were precipitated at
20 °C overnight after adding 20 µl of 3 M NaOAc and 1 ml of 100%
ethanol. Substrates were collected by centrifugation, washed once with
70% ethanol, and resuspended in sterile water.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (35K):
[in a new window]
Fig. 1.
In vitro interaction abilities of
human FEN-1 mutants to human PCNA. Each binding reaction
contains crude cell extract from E. coli cells that
individually overexpress the indicated histidine-tagged hFEN-1 mutant
protein plus crude cell extract from E. coli cells
overexpressing non-histidine-tagged hPCNA in the presence of
Ni2+-charged beads and binding buffer. Samples were gently
mixed, washed, and then proteins bound to Ni2+-charged
beads were eluted by boiling in sample buffer and recovering the
supernatant. The presence of both hFEN-1 and hPCNA bands in a single
lane indicates an in vitro complex of the two proteins.
Arrows on the left side indicate the
positions and sizes of molecular weight marker proteins.
Arrows on the right side indicate the positions
of the hFEN-1 and hPCNA proteins.

View larger version (25K):
[in a new window]
Fig. 2.
In vitro human PCNA-mediated
stimulation of endonuclease and exonuclease activities of mutant hFEN-1
proteins. A, flap endonuclease cleavage stimulation of
the wild type hFEN-1 and 8 mutant hFEN-1 proteins by hPCNA. Each
protein was assayed in the absence and presence of hPCNA as indicated.
Reactions were carried out as described under "Materials and
Methods." Uncleaved substrate and the 19- and 21-nucleotide cleavage
products are labeled to the left side.
Above the panel is a pictorial representation of
the flap endonuclease substrate used for all PCNA-dependent
nuclease activity assays; the asterisk indicates the
location of the 32P-labeled 5' end phosphate group. The
arrows indicate the cleavage sites that produce the 19-, 20-, and 21-nucleotide cleavage products. The bottom
panel is the -fold differences between flap endonuclease
activities with or without the presence of hPCNA. B,
exonuclease cleavage stimulation of the wild type hFEN-1 and 8 mutant
hFEN-1 proteins by hPCNA. Each protein was assayed in the absence and
presence of hPCNA as indicated. Reactions were carried out as described
under "Materials and Methods." Uncleaved substrate and the 1-, 2-, and 3-nucleotide cleavage products are labeled to the left
side. Above the panel is a pictorial
representation of the exonuclease substrate used for all
PCNA-dependent nuclease activity assays; the
asterisk indicates the location of the
32P-labeled 5' end phosphate group. The arrows
indicate the cleavage sites that produce the 1-, 2-, and 3-nucleotide
cleavage products. The bottom panel is the -fold
differences between exonuclease activities with or without the presence
of PCNA.

View larger version (37K):
[in a new window]
Fig. 3.
Intraspecies and interspecies binding
abilities of hFEN-1 and scRad27 to human and yeast PCNAs.
Binding experiments were performed as described previously using
histidine-tagged hFEN-1 or scRad27 crude cell extract,
non-histidine-tagged hPCNA or scPCNA crude cell extract,
Ni2+-charged beads, and binding buffer followed by analysis
on SDS-PAGE. Arrows on the left side
indicate the positions and sizes of molecular weight marker proteins.
Arrows on the right side indicate the
positions of the hFEN-1 or scRad27 protein and the human or yeast PCNA
proteins.

View larger version (42K):
[in a new window]
Fig. 4.
Intraspecies and interspecies PCNA-mediated
stimulation of endonuclease and exonuclease activities of hFEN-1 and
scRad27. The left side shows hPCNA
intraspecies- and interspecies-mediated stimulation of the endonuclease
and exonuclease activities of hFEN-1 and scRad27. The right
side shows scPCNA interspecies- and intraspecies-mediated
stimulation of the endonuclease and exonuclease activities of FEN-1 and
Rad27. Reactions were carried out as described in Fig. 2 using
identical amounts of proteins. Reactions were incubated at 30 °C for
15 min, quenched, analyzed using 15% PAGE, and visualized by
autoradiography. The nucleotide size markers for the endonuclease
activity are on the far left side of
the panel, and the ones for the exonuclease activity are on the
far right side.

View larger version (43K):
[in a new window]
Fig. 5.
Absence of the binding abilities of the 3A,
4A, 8A, and
P Rad27 mutants to scPCNA.
Binding experiments were performed as described in Fig. 3 using
histidine-tagged scRad27 mutant crude cell extracts and
non-histidine-tagged scPCNA. Results were analyzed using SDS-PAGE.
Arrows on the left side indicate the
positions and sizes of molecular weight marker proteins.
Arrows on the right side indicate the
positions of the scRad27 and scPCNA proteins.

View larger version (44K):
[in a new window]
Fig. 6.
In vitro scPCNA-mediated
stimulation of endonuclease and exonuclease activities of the 3A, 4A,
8A, and
P Rad27 mutants. Flap
endonuclease activity stimulation (solid gray on
left) and exonuclease activity stimulation
(striped on right) of the 3A, 4A, and 8A scRad27
mutants by scPCNA. Reactions were carried out as described in Fig. 2
legends. The -fold stimulation values in presence of PCNA were
calculated by normalizing the activity in absence of PCNA.
P) in order to eliminate 8 residues (Gln-337 through
Phe-344) in the PCNA binding motif. Results showed that FEN-1
P
completely lacked nuclease activity stimulation in
hPCNA-dependent assays. The authors concluded that the
physical interaction between hFEN-1 and hPCNA is absolutely required
for hFEN-1 stimulation. To further elucidate the meaning of our results
as well as the conclusion made by Stucki et al. (43), we
constructed two additional mutants in scRad27, in which we either
changed all 8 residues (Gln-340 through Phe-347) in the hPCNA binding
motif to alanines (termed the 8A mutant hereafter), or in which we
deleted all 8 residues (termed the
P mutant hereafter) in this region.
P mutants were deficient in their
ability to bind to scPCNA (Fig. 5). In contrast to what Stucki et
al. (43) has shown, our results revealed that both the 8A and
P
scRad27 mutants could have their endonuclease and exonuclease activities stimulated in the presence of the scPCNA (Fig. 6). This
phenomenon may explain the lack of observable phenotypes of S. cerevisiae cells containing a Rad27 gene harboring the F346A/F347A double mutation (44, 45). The F346A/F347A scRad27 mutant was unable to
produce significant phenotypic differences when incorporated in the
S. cerevisiae chromosome, probably due to that this double mutant's stimulation properties are similar to that of wild type.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
P
mutant). We assayed binding of these mutants to scPCNA and flap
endonuclease and exonuclease activity stimulation by scPCNA. As
expected, all of these mutants lost their ability to bind to scPCNA
(Fig. 5). All of the scRad27 proteins containing multiple mutations
(3A, 4A, and 8A) or a deletion (
P) also retained normal nuclease
activity stimulation mediated by scPCNA (Fig. 6).
P scRad27 mutant described here.
The sequences of these regions in the two proteins are identical except for 1 residue. They have carried out PCNA interaction and stimulation assays with their mutant and concluded that the PCNA interaction motif
is indispensable for stimulation of hFEN-1 activities by hPCNA. Our
results using proteins containing single mutant, multiple mutants, or a
deletion mutation in the C-terminal region required for in
vitro PCNA interaction did not result in significant loss of
stimulation. This discrepancy may have resulted from origins of
proteins, differences in experimental design, how the mutant proteins
were handled, or the removal of an additional amino acid residue,
Phe-347, in the yeast enzyme (deletion of 8 residues in scRad27
versus 7 residues in hFEN-1). Among these possibilities, the
deletion mutant protein that Stucki et al. and the one that we have constructed may have different folding properties, solubility, and consequently different biochemical functions. We have found that
the recombinant scRad27 proteins with multiple point mutations or
deletions are not as stable as wild type scRad27 nuclease. The most
deleterious case was the 8A mutant, where 8 amino acid residues
(337) were converted into a large cluster of alanines. Despite
this, we were able to purify the mutant proteins and perform the
nuclease activity assays. All of the mutants included in this study
have a wild type level of nuclease activities in PCNA-independent assays. Their nuclease activities could be stimulated by PCNA to a
level similar to that of the wild type nucleases. Therefore, the
stimulation that we observed with these mutants is most likely specific
and real. Several mutants, including 3A and 4A, were introduced into
rad27 null mutant cells using a yeast expression plasmid
(pDB20) and failed to show the significant phenotypes observed in the
rad27 null mutants, which is consistent with previous observations (42, 44, 45). This indicates that the activity stimulation
instead of the in vitro hFEN-1/hPCNA interaction is responsible for the functional deficiency observed in
vivo.
| |
ACKNOWLEDGEMENTS |
|---|
We thank John Termini, Tim O'Connor, Adam Bailis, Qing Chai, and other members in the Shen laboratory for their technical assistance and stimulating discussions during the course of this study. We are grateful for the opportunity to collaborate with J. A. Tainer laboratory at the Scripps Research Institute in solving the crystal structure of Pyrococcus furiosus FEN-1 nuclease, which is used as a template for molecular modeling in this study.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant CA73764 (to B. H. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
These authors contributed to this work equally.
§ To whom correspondence should be addressed: Dept. of Cell and Tumor Biology, City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010. Tel.: 626-301-8879; Fax: 626-301-8972; E-mail: bshen@coh.org.
Published, JBC Papers in Press, July 26, 2001, DOI 10.1074/jbc.M103397200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: FEN-1, flap endonuclease-1; hFEN-1, human flap endonuclease-1; PCNA, proliferating cell nuclear antigen; scPCNA, yeast proliferating cell nuclear antigen; hPCNA, human proliferating cell nuclear antigen; pol, polymerase; MCMT, DNA (cytosine-5) methyltransferase; XPG, xeroderma pigmentosum group G; PAGE, polyacrylamide gel electrophoresis; IDCL, interdomain connector loop; RF-C, replication factor C; oligo, oligonucleotide; BSA, bovine serum albumin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Lieber, M. R. (1996) BioEssays 19, 233-240 |
| 2. | Johnson, R. E., Kovvali, G. K., Prakash, L., and Prakash, S. (1995) Science 269, 238-240 |
| 3. | Shen, B., Qiu, J., Hosfield, D. J., and Tainer, J. A. (1998) Trends Biochem. Sci. 23, 171-173 |
| 4. | Bambara, R. A., Murante, R. S., and Henricksen, L. A. (1997) J. Biol. Chem. 272, 4647-4650 |
| 5. | Wu, X., Li, J., Li, X., Hsieh, C.-L., Burgers, P. M. J., and Lieber, M. R. (1996) Nucleic Acids Res. 24, 2036-2043 |
| 6. | Ceska, T. A., Sayers, J. R., Stier, G., and Suck, D. (1996) Nature 382, 90-93 |
| 7. | Hosfield, D. J., Mol, C. D., Shen, B., and Tainer, J. A. (1998) Cell 95, 135-146 |
| 8. | Hwang, K. Y., Baek, K., Kim, H. Y., and Cho, Y. (1998) Nat. Struct. Biol. 8, 707-713 |
| 9. | Kim, Y., Eom, S. H., Wang, J., Lee, D. S., Suh, S. W., and Steitz, T. A. (1995) Nature 376, 612-616 |
| 10. | Meusser, T. C., Nossal, N. G., and Hyde, C. C. (1996) Cell 85, 1101-1112 |
| 11. | Murante, R. S., Rust, L., and Bambara, R. A. (1995) J. Biol. Chem. 270, 30377-30383 |
| 12. | Qiu, J., Li, X., Frank, G. A., and Shen, B. (2001) J. Biol. Chem. 276, 4901-4908 |
| 13. | Biswas, E. E., Zhu, F. X., and Biswas, S. B. (1997) Biochemistry 36, 5955-5962 |
| 14. | Budd, M. E., and Campbell, J. L. (1997) Mol. Cell. Biol. 17, 2136-2142 |
| 15. | Li, X., Li, J., Harrington, J., Lieber, M. R., and Burgers, P. M. J. (1995) J. Biol. Chem. 270, 22109-22112 |
| 16. | Prasad, R., Dianov, G. L., Bohr, V., and Wilson, S. H. (2000) J. Biol. Chem. 275, 4460-4466 |
| 17. | Siegel, G., Turchi, J. J., Myers, T. W., and Bambara, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9377-9381 |
| 18. | Zhu, F. X., Biswas, E. E., and Biswas, S. B. (1997) Biochemistry 36, 5947-5954 |
| 19. | Fukuda, K., Morioka, H., Imajou, S., Ikeda, S., Ohtsuka, E., and Tsurimoto, T. (1995) J. Biol. Chem. 270, 22527-22534 |
| 20. | Zhang, S.-J., Zeng, X.-R., Zhang, P., Toomey, N. L., Chuang, R.-Y., Chang, L.-S., and Lee, M. Y. W. T. (1995) J. Biol. Chem. 270, 7988-7992 |
| 21. | Eissenberg, J. C., Ayyagari, R., Gomes, X. V., and Burgers, P. M. J. (1997) Mol. Cell. Biol. 17, 6367-6378 |
| 22. | Kelman, Z., and O'Donnell, M. (1995) Nucleic Acids Res. 23, 3613-3620 |
| 23. | Gary, R., Ludwig, D. L., Cornelius, H. L., MacInnes, M. A., and Park, M. S. (1997) J. Biol. Chem. 272, 24522-24529 |
| 24. | Chuang, L. S.-H., Ian, H.-I., Koh, T.-W., Ng, H.-H., Xu, G., and Li, B. F. L. (1997) Science 277, 1996-2000 |
| 25. | Nakanishi, M., Robetorye, R. S., Pereira-Smith, O. M., and Smith, J. R. (1995) J. Biol. Chem. 270, 17060-17063 |
| 26. | Chen, C., Merrill, B. J., Lau, P. J., Holm, C., and Kolodner, R. D. (1999) Mol. Cell. Biol. 19, 7801-7815 |
| 27. | Johnson, R. E., Kovvali, G. K., Guzder, S. N., Amin, N. S., Holm, C., Habraken, Y., Sung, P., Prakash, L., and Prakash, S. (1996) J. Biol. Chem. 271, 27987-27990 |
| 28. | Burgers, P. M. J., and Yoder, B. L. (1993) J. Biol. Chem. 268, 19923-19926 |
| 29. | Podust, V. N., Tiwari, N., Stephen, S., and Fanning, E. (1998) J. Biol. Chem. 273, 31992-31999 |
| 30. | Krishna, T. S. R., Kong, X.-P., Gary, S., Burgers, P. M., and Kuriyan, J. (1994) Cell 79, 1233-1243 |
| 31. | Tom, S., Henricksen, L. A., and Bambara, R. A. (2000) J. Biol. Chem. 275, 10498-10505 |
| 32. | Warbrick, E., Lane, D. P., Glover, D. M., and Cox, L. S. (1997) Oncogene 14, 2313-2321 |
| 33. | Jónsson, Z. O., Hindges, R., and Hübscher, U. (1998) EMBO 17, 2412-2425 |
| 34. | Qiu, J., Qian, Y., Frank, P., Wintersberger, U., and Shen, B. (1999) Mol. Cell. Biol. 19, 8361-8371 |
| 35. | Rumbaugh, J. A., Murante, R. S., Shi, S., and Bambara, R. A. (1997) J. Biol. Chem. 271, 22591-22599 |
| 36. | Gary, R., Kim, K., Cornelius, H. L., Park, M. S., and Matsumoto, Y. (1999) J. Biol. Chem. 274, 4354-4363 |
| 37. | Kim, K., Biade, S., and Matsumoto, Y. (1998) J. Biol. Chem. 273, 8842-8848 |
| 38. | Klungland, A., and Lindahl, T. (1997) EMBO J. 16, 3341-3348 |
| 39. | Kokoska, R. J., Stefanovic, L., Buermeyer, A. B., Liskay, R. M., and Petes, T. D. (1999) Genetics 151, 511-519 |
| 40. | Tishkoff, D. X., Filosi, N., Gaida, G. M., and Kolodner, R. D. (1997) Cell 88, 253-263 |
| 41. | Nolan, J. P., Shen, B., Park, M. S., and Sklar, L. A. (1996) Biochemistry 36, 11668-11676 |
| 42. | Frank, G., Qiu, J., Somsouk, M., Weng, Y., Somsouk, L., Nolan, J. P., and Shen, B. (1998) J. Biol. Chem. 273, 33064-33072 |
| 43. | Stucki, M., Jónsson, Z. O., and Hübscher, U. (2001) J. Biol. Chem. 276, 7843-7849 |
| 44. | Gary, R., Park, M. S., Nolan, J. P., Cornelius, H. L., Kozyreva, O. G., Tran, H. T., Lobachev, K. S., Resnick, M. A., and Gordenin, D. A. (1999) Mol. Cell. Biol. 19, 5373-5382 |
| 45. | Greene, A. L., Snipe, J. R., Gordenin, D. A., and Resnick, M. A. (1999) Hum. Mol. Genet. 8, 2263-2273 |
| 46. | Levin, D. S., Bai, W., Yao, N., O'Donnell, M., and Tomkinson, A. E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12863-12868 |
| 47. | Montecucco, A., Rossi, R., Levin, D. S., Gary, R., Park, M. S., Motycka, T. A., Ciarrocchi, G., Villa, A., Biamonti, G., and Tomkinson, A. E. (1998) EMBO J. 17, 3786-3795 |
| 48. | Gomes, X. V., and Burgers, P. M. J. (2000) EMBO 19, 3811-3821 |
This article has been cited by other articles:
![]() |
L. Zheng, H. Dai, J. Qiu, Q. Huang, and B. Shen Disruption of the FEN-1/PCNA Interaction Results in DNA Replication Defects, Pulmonary Hypoplasia, Pancytopenia, and Newborn Lethality in Mice Mol. Cell. Biol., April 15, 2007; 27(8): 3176 - 3186. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Singh, L. Zheng, V. Chavez, J. Qiu, and B. Shen Concerted Action of Exonuclease and Gap-dependent Endonuclease Activities of FEN-1 Contributes to the Resolution of Triplet Repeat Sequences (CTG)n- and (GAA)n-derived Secondary Structures Formed during Maturation of Okazaki Fragments J. Biol. Chem., February 9, 2007; 282(6): 3465 - 3477. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Mortusewicz, U. Rothbauer, M. C. Cardoso, and H. Leonhardt Differential recruitment of DNA Ligase I and III to DNA repair sites Nucleic Acids Res., July 19, 2006; 34(12): 3523 - 3532. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sporbert, P. Domaing, H. Leonhardt, and M. C. Cardoso PCNA acts as a stationary loading platform for transiently interacting Okazaki fragment maturation proteins Nucleic Acids Res., June 21, 2005; 33(11): 3521 - 3528. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Qiu, R. Liu, B. R. Chapados, M. Sherman, J. A. Tainer, and B. Shen Interaction Interface of Human Flap Endonuclease-1 with Its DNA Substrates J. Biol. Chem., June 4, 2004; 279(23): 24394 - 24402. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Spiro and C. T. McMurray Nuclease-Deficient FEN-1 Blocks Rad51/BRCA1-Mediated Repair and Causes Trinucleotide Repeat Instability Mol. Cell. Biol., September 1, 2003; 23(17): 6063 - 6074. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Lau, H. Flores-Rozas, and R. D. Kolodner Isolation and Characterization of New Proliferating Cell Nuclear Antigen (POL30) Mutator Mutants That Are Defective in DNA Mismatch Repair Mol. Cell. Biol., October 1, 2002; 22(19): 6669 - 6680. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Qiu, D. N. Bimston, A. Partikian, and B. Shen Arginine Residues 47 and 70 of Human Flap Endonuclease-1 Are Involved in DNA Substrate Interactions and Cleavage Site Determination J. Biol. Chem., June 28, 2002; 277(27): 24659 - 24666. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dua, D. L. Levy, C. M. Li, P. M. Snow, and J. L. Campbell In Vivo Reconstitution of Saccharomyces cerevisiae DNA Polymerase epsilon in Insect Cells. PURIFICATION AND CHARACTERIZATION J. Biol. Chem., March 1, 2002; 277(10): 7889 - 7896. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shibata and T. Nakamura Defective Flap Endonuclease 1 Activity in Mammalian Cells Is Associated with Impaired DNA Repair and Prolonged S Phase Delay J. Biol. Chem., January 4, 2002; 277(1): 746 - 754. [Abstract] [Full Text] |
||||
| |||||||||||||||||